Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Nomenclature

Drug Nomenclature

During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that the same...

FDA Approved Drugs: Changes to Approved Drugs

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Drug Products: Biologics, Biosimilars and Interchangeables

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

Drug Regulation

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...

Clinical Trials

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Development of a Web Platform to Facilitate the Implementation and Evaluation of Health Promoting Schools: Protocol for a Double Diamond Design Approach.

JMIR research protocols·2024

Same author

Sustaining Meaningful Patient Engagement Across the Lifecycle of Medicines: A Roadmap for Action.

Therapeutic innovation & regulatory science·2021

Same author

Evaluation of patient engagement in medicine development: A multi-stakeholder framework with metrics.

Health expectations : an international journal of public participation in health care and health policy·2021

Same author

Understanding multi-stakeholder needs, preferences and expectations to define effective practices and processes of patient engagement in medicine development: A mixed-methods study.

Health expectations : an international journal of public participation in health care and health policy·2021

Same author

Evaluating the "return on patient engagement initiatives" in medicines research and development: A literature review.

Health expectations : an international journal of public participation in health care and health policy·2019

Same author

Tolvaptan for the treatment of hyponatremia and congestive heart failure.

Drugs of today (Barcelona, Spain : 1998)·2010

Search research articles

Related Experiment Video

Updated: Jun 11, 2026

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

Pharmaceutical trademarks: navigating through the FDA's pilot program.

¹ferrer.elisa@gmail.com

Drug News & Perspectives

|July 7, 2010

Summary

This summary is machine-generated.

Navigating pharmaceutical trademark clearance is complex. The FDA

More Related Videos

Optogenetic Functional MRI

Optogenetic Functional MRI

Published on: April 19, 2016

Radiosynthesis of 1-(2-[18F]Fluoroethyl)-L-Tryptophan using a One-pot, Two-step Protocol

Radiosynthesis of 1-(2-[¹⁸F]Fluoroethyl)-L-Tryptophan using a One-pot, Two-step Protocol

Published on: September 21, 2021

Related Experiment Videos

Last Updated: Jun 11, 2026

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

Optogenetic Functional MRI

Optogenetic Functional MRI

Published on: April 19, 2016

Radiosynthesis of 1-(2-[18F]Fluoroethyl)-L-Tryptophan using a One-pot, Two-step Protocol

Radiosynthesis of 1-(2-[¹⁸F]Fluoroethyl)-L-Tryptophan using a One-pot, Two-step Protocol

Published on: September 21, 2021

Area of Science:

Pharmaceutical Law
Intellectual Property
Regulatory Affairs

Background:

Pharmaceutical trademark creation and clearance present significant legal challenges.
The Food and Drug Administration (FDA) has introduced a pilot program to streamline this process.

Purpose of the Study:

To review the FDA's pilot program for pharmaceutical trademark evaluation.
To outline data requirements and potential issues in submitting trademarks to the FDA.
To discuss the implications of the pilot program for clearing new pharmaceutical marks.

Main Methods:

Analysis of the FDA's pilot program under the Prescription Drug User Fee Act (PDUFA) IV.
Review of expert discussions from a Thomson Reuters webinar on trademark development.
Examination of approaches to trademark evaluation in light of FDA perspectives.

Main Results:

The FDA pilot program aims to facilitate the evaluation of proposed pharmaceutical marks.
Understanding data submission requirements and potential challenges is crucial for successful clearance.
The program signifies potential changes in how new pharmaceutical trademarks are cleared.

Conclusions:

The FDA pilot program offers a structured approach to pharmaceutical trademark review.
Proactive evaluation and data preparation are essential for navigating FDA trademark submissions.
Expert insights provide guidance on adapting trademark strategies to regulatory expectations.